Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Stoke Therapeutics (STOK) Shares Outstanding (Weighted Average): 2018-2024

Historic Shares Outstanding (Weighted Average) for Stoke Therapeutics (STOK) over the last 7 years, with Dec 2024 value amounting to $53.0 million.

  • Stoke Therapeutics' Shares Outstanding (Weighted Average) rose 4.08% to $54.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $54.8 million, marking a year-over-year increase of 4.08%. This contributed to the annual value of $53.0 million for FY2024, which is 18.62% up from last year.
  • Per Stoke Therapeutics' latest filing, its Shares Outstanding (Weighted Average) stood at $53.0 million for FY2024, which was up 18.62% from $44.7 million recorded in FY2023.
  • In the past 5 years, Stoke Therapeutics' Shares Outstanding (Weighted Average) ranged from a high of $53.0 million in FY2024 and a low of $33.5 million during FY2020.
  • Moreover, its 3-year median value for Shares Outstanding (Weighted Average) was $44.7 million (2023), whereas its average is $45.7 million.
  • Data for Stoke Therapeutics' Shares Outstanding (Weighted Average) shows a peak YoY rose of 18.62% (in 2024) over the last 5 years.
  • Stoke Therapeutics' Shares Outstanding (Weighted Average) (Yearly) stood at $33.5 million in 2020, then rose by 9.92% to $36.8 million in 2021, then grew by 7.18% to $39.4 million in 2022, then rose by 13.25% to $44.7 million in 2023, then rose by 18.62% to $53.0 million in 2024.